文献速递心脑血管急症消化、代谢与肾脏急症

海洋n-3脂肪酸与心血管疾病和癌症预防

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
PubMed 文献 · N Engl J Med · 2018-11-10
一句话结论在普通风险人群中,每日补充1克海洋n-3脂肪酸未降低主要心血管事件或浸润性癌症发生率。

该随机、安慰剂对照、2×2析因试验纳入美国50岁以上男性和55岁以上女性共25871人,比较每日2000 IU维生素D3与每日1克海洋n-3脂肪酸对心血管疾病和癌症的一级预防作用。中位随访5.3年,n-3组主要心血管事件386例 vs 安慰剂组419例(HR 0.92,95%CI 0.80-1.06,P=0.24),浸润性癌症820例 vs 797例(HR 1.03,95%CI 0.93-1.13,P=0.56),均无显著差异。总心肌梗死HR 0.72(95%CI 0.59-0.90)为关键次要终点中的阳性结果,但总卒中、心血管死亡、癌症死亡及全因死亡均无显著差异,未观察到出血或其他严重不良事件风险增加。

要点

  • 每日1克海洋n-3脂肪酸补充未降低主要心血管事件(HR 0.92,95%CI 0.80-1.06,P=0.24)或浸润性癌症(HR 1.03,95%CI 0.93-1.13,P=0.56)发生率。
  • 总心肌梗死HR 0.72(95%CI 0.59-0.90)为次要终点中的阳性信号,但总卒中(HR 1.04)、心血管死亡(HR 0.96)、癌症死亡(HR 0.97)及全因死亡(HR 1.02)均无显著差异。
  • 未观察到出血或其他严重不良事件风险增加。
  • 适用人群为美国50岁以上男性和55岁以上女性,中位随访5.3年。

适用人群与场景

  • 美国50岁及以上男性和55岁及以上女性,来自一般人群,用于心血管疾病和癌症的一级预防。

处置流程与药物剂量

  • 干预为海洋n-3脂肪酸每日1克口服,对照为安慰剂;同时按2×2析因设计另有维生素D3每日2000 IU分组,本文报告n-3脂肪酸与安慰剂的比较。

研究设计与关键结果

  • 随机、安慰剂对照、2×2析因试验,共25871名参与者(包括5106名黑人参与者)接受随机化,中位随访5.3年。
  • 主要心血管事件:n-3组386例 vs 安慰剂组419例,HR 0.92(95%CI 0.80-1.06),P=0.24。
  • 浸润性癌症:n-3组820例 vs 安慰剂组797例,HR 1.03(95%CI 0.93-1.13),P=0.56。
  • 关键次要终点:扩展心血管复合终点HR 0.93(95%CI 0.82-1.04);总心肌梗死HR 0.72(95%CI 0.59-0.90);总卒中HR 1.04(95%CI 0.83-1.31);心血管原因死亡HR 0.96(95%CI 0.76-1.21);癌症死亡(341例癌症死亡)HR 0.97(95%CI 0.79-1.20)。
  • 全因死亡(共978例死亡)HR 1.02(95%CI 0.90-1.15)。
  • 未观察到出血或其他严重不良事件风险增加。

证据类型、等级与局限

  • 证据类型:随机、安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于美国50岁以上男性和55岁以上女性,每日补充1克海洋n-3脂肪酸未显示可降低主要心血管事件或浸润性癌症发生率。
  • 总心肌梗死HR 0.72(95%CI 0.59-0.90)为次要终点结果,不能据此改变一级预防中常规补充n-3脂肪酸的做法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Higher intake of marine n-3 (also called omega-3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether supplementation with n-3 fatty acids has such effects in general populations at usual risk for these end points is unclear.

METHODS: We conducted a randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes) and invasive cancer of any type. Secondary end points included individual components of the composite cardiovascular end point, the composite end point plus coronary revascularization (expanded composite of cardiovascular events), site-specific cancers, and death from cancer. Safety was also assessed. This article reports the results of the comparison of n-3 fatty acids with placebo.

RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Invasive cancer was diagnosed in 820 participants in the n-3 group and in 797 in the placebo group (hazard ratio, 1.03; 95% CI, 0.93 to 1.13; P=0.56). In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21); and for death from cancer (341 deaths from cancer), 0.97 (95% CI, 0.79 to 1.20). In the analysis of death from any cause (978 deaths overall), the hazard ratio was 1.02 (95% CI, 0.90 to 1.15). No excess risks of bleeding or other serious adverse events were observed.

CONCLUSIONS: Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2018. PMID: 30415637. doi:10.1056/NEJMoa1811403

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。